Drug Intelligence
Regional and national signals, compared against your own program
What is coming toward your program
Powered by DrugTrends.us. Signals are ranked by relevance to your region and your recent positivity.
regionalNorth TexasDrugTrends.us regional brief · Aug 29
Xylazine co-positivity rising across North Texas
Xylazine appeared in 31% of fentanyl-positive specimens in DFW-area programs in August, up from 18% in May. Wound-care and naloxone-non-response education recommended.
XYL
Your program
9.4%
Benchmark
7.1%
2.3 pts above benchmark
emergingDrugTrends.us emerging-substance watch · Aug 26
Medetomidine detected in Southwest samples
A veterinary sedative similar to xylazine, medetomidine is appearing in a small but growing share of fentanyl samples. Standard panels do not detect it; confirm expanded panel coverage.
MDA
Not in your current program panels. Check expanded-panel coverage from the Create Drug Test flow.
nationalDrugTrends.us quarterly · Aug 15
Fentanyl positivity plateauing nationally, still elevated
National behavioral-health positivity for fentanyl held at 12.6% in Q2, flat quarter over quarter. Your program is above benchmark.
FEN
Your program
13.4%
Benchmark
12.6%
0.8 pts above benchmark
nationalDrugTrends.us national brief · Aug 12
Nitazene detections up in 14 states
Synthetic opioids in the nitazene class continue to spread. Texas reported 3 confirmed detections in July. Most 12-panel screens will not flag nitazenes.
NIT
Not in your current program panels. Check expanded-panel coverage from the Create Drug Test flow.
regionalTexasDrugTrends.us regional brief · Aug 29
Methamphetamine steady, purity high
No significant regional change in methamphetamine positivity. Your program is roughly at benchmark.
MAMP
Your program
10.9%
Benchmark
11.3%
0.4 pts below benchmark